EU and US could reach trade deal this weekend - Reuters
PALO ALTO, Calif. - Guardant Health, Inc. (NASDAQ: GH), a precision oncology company valued at approximately $5 billion, has introduced a complete suite of immunohistochemistry (IHC) testing for key biomarkers in solid tumors. This new offering aims to aid oncologists in identifying tumor subtypes and selecting the most effective targeted therapies for cancer patients. The company has demonstrated strong growth with revenue increasing 28.2% over the last twelve months, according to InvestingPro data.
The IHC testing process involves special staining to detect specific proteins within tissue samples, which are indicative of tumor biomarkers. These biomarkers are crucial for determining the characteristics of a tumor and guiding the choice of targeted cancer therapy. The suite includes comprehensive testing for biomarkers such as HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1, which are relevant to various cancer types including lung, breast, gastric, and ovarian cancers. The company maintains a healthy gross profit margin of 61.34% and strong liquidity, with current assets significantly exceeding short-term obligations.
The addition of IHC testing complements the Guardant360 Tissue multiomic profiling test, which was recently introduced. "This expansion of our portfolio will allow us to offer cancer care teams more comprehensive tissue testing capabilities through a single source," stated Helmy Eltoukhy, chairman and co-CEO of Guardant Health.
One of the key biomarkers the IHC tests can identify is c-MET, which is significant for patients with non-squamous non-small cell lung cancer (NSCLC) expressing this protein. The U.S. Food and Drug Administration (FDA) recently approved Emrelis™ (telisotuzumab vedotin-tllv), an antibody-drug conjugate for the treatment of c-MET-expressing NSCLC.
Guardant Health, founded in 2012, focuses on transforming patient care and accelerating the development of new cancer therapies through its advanced blood and tissue tests, real-world data, and AI analytics.
The press release also contains forward-looking statements regarding the potential benefits of Guardant Health’s tests. However, these statements are subject to risks and uncertainties that could cause actual results to differ from expectations. While eight analysts have recently revised their earnings estimates upward for the upcoming period, InvestingPro analysis indicates the company may not achieve profitability this year. For comprehensive insights into Guardant Health’s financial health and future prospects, investors can access the detailed Pro Research Report, available exclusively to InvestingPro subscribers, along with additional expert analysis and financial metrics.
The information in this article is based on a press release statement from Guardant Health, Inc.
In other recent news, Guardant Health reported its first-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of -$0.49 against the forecasted -$0.75. The company also reported higher-than-expected revenue of $203.5 million, exceeding the anticipated $190.01 million. Following this strong financial performance, Scotiabank raised its price target for Guardant Health to $57, maintaining a Sector Outperform rating, while Canaccord Genuity increased its target to $65 and upheld a Buy rating. These adjustments reflect Guardant Health’s robust start to the year, characterized by a significant increase in revenue and test volume.
Guardant Health’s recent developments include the introduction of the Guardant Hereditary Cancer test, designed to identify genetic variants that increase the risk of developing cancer. This new test is part of the company’s broader portfolio aimed at supporting healthcare providers throughout the continuum of cancer care. The company also announced the launch of its upgraded Guardant360 Tissue test, which requires 40% less tissue than previous versions. This innovation aims to enhance the company’s multi-omic testing capabilities.
Additionally, Guardant Health has raised its full-year 2025 revenue guidance to $880-$890 million, indicating a 19-20% year-over-year growth. The company plans to reinvest some of its financial gains into its commercial infrastructure while maintaining its aim to reach cash flow breakeven by 2028. The firm’s strategic focus on innovation and expanding its market presence is evident in its recent product launches and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.